Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaxCyte Share News (MXCT)

Share Price Information for MaxCyte (MXCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 380.00
Bid: 374.00
Ask: 386.00
Change: 0.00 (0.00%)
Spread: 12.00 (3.209%)
Open: 380.00
High: 380.00
Low: 380.00
Prev. Close: 380.00
MXCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MaxCyte revenue grows in 2022, expects further revenue climb in 2023

Tue, 07th Mar 2023 10:51

(Alliance News) - MaxCyte Inc on Tuesday announced a higher revenue for 2022, and said it anticipates revenue to grow further during 2023.

The Maryland, US-based commercial cell-engineering company with an office in Cheshire, England will release its annual results next week Wednesday.

For the fourth quarter of 2022, MaxCyte anticipates growth of around 22% to about USD12.4 million from USD10.2 million. Meanwhile, for 2022 as a whole, it expects a 31% climb to USD44.3 million from USD33.9 million.

Further, for 2023, the company expects revenue growth between 21% and 26% and strategic platform license programme-related revenue of around USD6 million, compared to around USD4.6 million in 2022.

"Our diverse and robust partnership portfolio continues to grow with three new partnerships added in 2022, in addition to the signing of a partnership with Vertex Pharmaceuticals following the transfer from CRISPR Therapeutics for the development of its CRISPR/Cas9-based gene-edited therapy," said Chief Executive Officer Doug Doerfler.

The company made no mention of profit or loss expectations. In 2021, it had a net loss of USD19.1 million, widened 62% from USD11.8 million in 2020.

MaxCyte shares were 5.0% lower at 370.50 pence each in London on Tuesday morning.

By Tom Budszus, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
8 May 2019 15:58

MaxCyte begins dosing second cohort in MCY-M11 clinical trial

(Sharecast News) - Clinical-stage, cell-based therapies and life sciences company MaxCyte has initiated dosing for the second cohort of patients in its US phase 1 clinical trial with MCY-M11 - the lead, wholly-owned, non-viral mRNA-based cell therapy candidate from its CARMA platform - it announced on Wednesday.

Read more
8 May 2019 12:11

MaxCyte Dosing Second Patients Group In Phase One Cancer Drug Trial

LONDON (Alliance News) - MaxCyte Inc on Wednesday said it has begun dosing for the second cohort of patients in its phase one trial of cancer drug MCY-M11.Shares in MaxCyte were down 5.7% a

Read more
24 Apr 2019 11:37

MaxCyte Outlook Confident As Loss Narrows In 2018 On Higher Revenue

LONDON (Alliance News) - MaxCyte Inc on Wednesday said its loss narrowed in 2018 on higher annual fees from its partners as it progresses on MCY-M11 therapeutic candidate development.The a

Read more
17 Apr 2019 16:06

UK Earnings, Trading Statements Calendar - Next 7 Days

Thursday 18 April UnileverQ1 ResultsPZ CussonsTrading SolutionsTrading 19 events

Read more
8 Apr 2019 13:58

MaxCyte Launches ExPERT Cellular Engineering Technology Platform

LONDON (Alliance News) - MaxCyte Inc on Monday announced the launch of its new ExPERT technology platform for use in cellular engineering.MaxCyte also noted that its business had produced

Read more
8 Apr 2019 08:34

MaxCyte launches new generation of cellular engineering instruments

(Sharecast News) - MaxCyte on Monday launched its ExPERT technology platform, a family of instruments that are the next generation of its complex cellular engineering technology.

Read more
1 Mar 2019 10:05

MaxCyte Inks Multi-Drug Clinical And Commercial Agreement With Kite

LONDON (Alliance News) - Biotechnology company MaxCyte Inc on Friday said it has expanded its business relationship with Kite by signing a multi-drug clinical and commercial agreement.Under

Read more
5 Feb 2019 17:45

UPDATE: MaxCyte Placing Fully Subscribed; Raises Over GBP10.0 Million (ALLISS)

LONDON (Alliance News) - MaxCyte Inc on Tuesday said it has raised GBP10.0 million from a placing of 5.9 million shares at 170 pence each.The life sciences company placed 5.9 million just

Read more
5 Feb 2019 10:22

MaxCyte To Raise At Least GBP10 Million For Future Growth Plans (ALLISS)

LONDON (Alliance News) - MaxCyte Inc on Tuesday said it plans to raise at least GBP10 million via a placing of shares in order to accelerate its growth strategy.The life sciences company no

Read more
15 Jan 2019 11:18

MaxCyte Guides For Revenue Growth And Earnings Above Expectations

LONDON (Alliance News) - MaxCyte Inc on Tuesday guided for a 19% increase in its 2018 revenue with the firm expecting its annual earnings to exceed market views.The life science company in

Read more
24 Oct 2018 16:07

UK Shareholder Meetings Calendar - Next 7 Days

Thursday 25 OctoberGreen & Smart WoodsAlumasc GroupFriday 26 OctoberArgos Capital

Read more
10 Oct 2018 11:47

MaxCyte Begins Patient Trial Of Proposed Cancer Treatment MCY-M11

LONDON (Alliance News) - Life sciences and medicines company MaxCyte Inc on Wednesday said it has dosed the first patient in its phase I trial for MCY-M11.MCY-M11 is a mesothelin targeting

Read more
24 Sep 2018 10:18

MaxCyte Interim Revenue Rises But Loss Widens On CARMA Development

LONDON (Alliance News) - MaxCyte Inc on Monday said its loss widened in the first half of 2018 as it continued to invest in the development of its CARMA drug platform.The life sciences said

Read more
17 Sep 2018 16:09

UK Earnings, Trading Statements Calendar - Next 7 Days

Tuesday 18 September Ocado GroupTrading Statement DP PolandHalf Year Year Year Year

Read more
26 Jul 2018 17:50

DIRECTOR DEALINGS: Wife Of MaxCyte Non-Executive Director Buys Shares

LONDON (Alliance News) - Medical & technology company MaxCyte Inc said that Karin Johnston, wife of Non-Executive Director John Johnston, purchased 11,500 shares at a price of 240 pence per on

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.